MedTrace Logo

Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

NCT06900647 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-04-02

No results posted yet for this study

Summary

This a phase 1 study to evaluate the safety and preliminary efficacy of cisplatin combined with bortezomib in patients with recurrent or metastatic breast cancer.

Conditions

Interventions

DRUG

Bortezomib (B)

1.3mg/m2, IV, D1, D4, D8 and D11, every 3 weeks

DRUG

Cisplatin (CDDP)

50mg/m2, IV, D1-3, every 3 weeks

DRUG

Bortezomib (B)

1.5mg/m2, IV, D1, D4, D8 and D11, every 3 weeks

DRUG

Bortezomib (B)

1.7mg/m2, IV, D1, D4, D8 and D11, every 3 weeks

DRUG

Cisplatin (CDDP)

70mg/m2, IV, D1-3, every 3 weeks

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Yan-xia Shi, Doctor · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-06-30
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06900647 on ClinicalTrials.gov